PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events
ME Staff 8-k
PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events Item 8.01 Other Events.
Beginning August 23, 2019, PharmaCyte Biotech, Inc. (“PharmaCyte”) mailed to its stockholders a Notice of Special Meeting of Stockholders and Proxy Statement (“Notice and Proxy Statement”) related to its Special Meeting of Stockholders (“Special Meeting”) to be held at the Courtyard by Marriott located at 7955 Irvine Center Drive, Irvine, California 92618 on Wednesday, September 11, 2019 at 11:00 a.m. Pacific Daylight Time to consider and vote on the following matters:
PharmaCyte Biotech, Inc. Exhibit EX-99.1 2 pharma_ex9901.htm NOTICE OF ANNUAL MEETING OF STOCKHOLDERS AND PROXY STATEMENT Exhibit 99.1 PHARMACYTE BIOTECH,… To view the full exhibit click here
About PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB)
PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company’s Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. The Company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.
